Dr. Bill Kohlbrenner Joins BioLoomics
BioLoomics is excited to welcome Dr. Bill Kohlbrenner to the team as Vice President of Business Development. Prior to joining BioLoomics, Bill has had a fruitful career in pharma ...
10
09, 2021
6
07, 2021
2021 Virtual KAND Family & Scientific Engagement Conference
Join us July 9th and 10th for the KAND Family & Scientific Engagement Conference hosted by KIF1A.ORG. Register here to join the conversation and learn about the latest research and ...
24
06, 2021
BioLoomics & KIF1A.ORG search for Treatments and a Cure for KAND
BioLoomics is joining KIF1A.ORG in its search for a treatment and cure for KIF1A-Associated Neurological Disorder (KAND). We are applying our evolution-in-a-microscope technology to build high throughput drug discovery ...
15
05, 2021
Dr. Michael Stowell Joins Scientific Advisory Board
BioLoomics is forming a Scientific Advisory Board (SAB) to bring together diverse experts to bolster our mission to produce drug discovery assays and the first biosensing biologics with enhanced specificity ...
11
05, 2021
BioLoomics Closed $575,000 Seed Funding Round
BioLoomics closed a $575,000 round of seed funding on May 11, 2021. The funds were contributed by private investors, including several investors who participated in the pre-seed round. BioLoomics will ...